EPIVAX, INC.

Company Information
Address 146 CLIFFORD STREET
PROVIDENCE, RI, -


Information

DUNS: 135531015

# of Employees: N/A


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. Novel Antigen-Specific Immunomodulatory Tregitope-based Therapy to Address Autoimmune Pathogenesis in Graves' Disease

    Amount: $177,020.00

    ABSTRACT Significance Graves disease GD one of the most prevalent autoimmune diseases is caused by stimulating autoantibodies TSAb to the Thyroid Stimulating Hormone Receptor TSHR resulting ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  2. Development of a Non-adjuvanted VLP Vaccine against Stealth H7N9 Influenza

    Amount: $590,546.00

    DESCRIPTION provided by applicant The avian origin H N influenza virus that emerged in humans in China in presents a unique challenge to vaccine development because it is poorly immunogenic ...

    SBIRPhase I2016Department of Health and Human Services National Institutes of Health
  3. EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of

    Amount: $1,474,236.00

    DESCRIPTION (provided by applicant): The goal of this Phase II project is to advance the development of novel tolerance-inducing peptides (Tregitopes) to prevent and/or treat Type 1 diabetes (T1D) by ...

    SBIRPhase II2012Department of Health and Human Services
  4. Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease Pompe disease is a lysosomal storage disorder caused by defects in the enzyme acid alpha-glucosi ...

    SBIRPhase I2012Department of Health and Human Services
  5. Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A

    Amount: $757,712.00

    DESCRIPTION (provided by applicant): The goal of this new SBIR program is to produce a combined clotting Factor VIII replacement and immunomodulatory therapy that will provide FVIII-specific tolerance ...

    SBIRPhase I2012Department of Health and Human Services
  6. T1D Tolerance Induction with Natural Treg Epitopes

    Amount: $599,999.00

    DESCRIPTION (provided by applicant): Type 1 (juvenile) diabetes is an organ-specific autoimmune disease resulting from destruction of insulinproducing pancreatic beta-cells. In non-diabetics, islet ce ...

    SBIRPhase I2008Department of Health and Human Services
  7. Optimization of a Multivalent Tuberculosis Vaccine

    Amount: $299,908.00

    DESCRIPTION (provided by applicant): This new Phase I SBIR proposal addresses the continuing worldwide need for a tuberculosis (TB) vaccine. We detail a novel multivalent strategy that aims to elicit ...

    SBIRPhase I2007Department of Health and Human Services
  8. Epitope-driven deimmunization of Factor VIII

    Amount: $263,867.00

    DESCRIPTION (provided by applicant): Hemophilia A patients are prone to develop inhibitory immune responses to the very therapy they require: Factor VIII protein replacement. Up to 30% of all hemophil ...

    SBIRPhase I2007Department of Health and Human Services
  9. A Genome-Derived, Epitope-Driven H. Pylori Vaccine

    Amount: $609,910.00

    DESCRIPTION (provided by applicant): EpiVax discovers and develops epitqpe-driven vaccines by screening microbial genomes for protective epitopes. In this application, we describe a genome-based appr ...

    SBIRPhase I2005Department of Health and Human Services
  10. Novel Smallpox Vaccine Derived from VV/VAR Immunome

    Amount: $1,027,410.00

    DESCRIPTION (provided by applicant): EpiVax specializes in the development of epitope-driven vaccines by screening whole genomes for candidate vaccine components. In this application, we propose to de ...

    SBIRPhase I2005Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government